Education
About Us
Working with TipRanks
Follow Us
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
AGN Stock Chart & Stats
AU$0.22
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.22
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.86
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$28.26M
Enterprise ValueAU$21.94M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.64Price Target Upside190.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Bulls Say, Bears Say
Bulls Say
Zero DebtZero reported debt reduces refinancing and interest burden risk, giving management flexibility to fund R&D via equity, grants, or partnerships. For an early-stage biotech, a debt-free balance sheet lengthens optionality and protects operations against credit market stress.
Top-line GrowthSequential revenue growth indicates progressing commercial traction or non-dilutive funding (grants/milestones) and provides external validation of the company’s activities. Sustained top-line expansion supports partnership, licensing, or milestone-based financing options over the medium term.
Improving Free Cash Flow TrendYear-over-year improvement in free cash flow signals better operational efficiency or expense control. While still negative, a durable improvement trend can extend runway, lower immediate dilution risk and enable more predictable planning for clinical milestones and partner discussions.
Bears Say
Large Cash BurnSustained negative operating and free cash flow near -5.7M annually constitutes a structural cash burn that will require external funding to sustain operations and trials. Persistent burn increases dilution risk, compresses runway for clinical programs, and can force suboptimal financing or partnership timing.
Deep Negative MarginsVery large negative net and EBIT margins show the cost base far exceeds current revenue, indicating no near-term path to profitability. Structurally negative margins make the business dependent on successful clinical outcomes or continual capital raises, limiting internal value capture.
Declining Shareholder EquityA sharp drop in shareholder equity reflects capital consumption from losses and reduces the balance-sheet buffer. This erosion heightens reliance on external capital, increases the probability of dilutive financings, and weakens financial flexibility to fund development programs independently.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.19 and its highest was AU$0.86 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$28.26M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 358 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.64 (190.91% Upside)
AU$0.64 (190.91% Upside)
Blogger Sentiment
Bullish
AU:AGN Sentiment 93%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-67.68%
Trailing 12-Months
Asset Growth
-32.60%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
AGN Stock 12 Month Forecast
Average Price Target
AU$0.64
▲(190.91% Upside)
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---